BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19002168)

  • 21. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma.
    Cho-Vega JH; Tsavachidis S; Do KA; Nakagawa J; Medeiros LJ; McDonnell TJ
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2615-22. PubMed ID: 18086765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nin one binding protein expression as a prognostic marker in prostate carcinoma.
    Liu G; Shen D; Jiao L; Sun Y
    Clin Transl Oncol; 2014 Sep; 16(9):843-7. PubMed ID: 24493285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated TEAD1 Expression is not an Independent Prognosis Factor of Hepatocellular Carcinoma.
    Hu X; He B; Zhou L; Zheng S
    Clin Lab; 2018 May; 64(5):743-748. PubMed ID: 29739039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer.
    Timofeeva OA; Palechor-Ceron N; Li G; Yuan H; Krawczyk E; Zhong X; Liu G; Upadhyay G; Dakic A; Yu S; Fang S; Choudhury S; Zhang X; Ju A; Lee MS; Dan HC; Ji Y; Hou Y; Zheng YL; Albanese C; Rhim J; Schlegel R; Dritschilo A; Liu X
    Oncotarget; 2017 Apr; 8(14):22741-22758. PubMed ID: 28009986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological significance of ARID1B in breast invasive ductal carcinoma.
    Shao F; Guo T; Chua PJ; Tang L; Thike AA; Tan PH; Bay BH; Baeg GH
    Histopathology; 2015 Nov; 67(5):709-18. PubMed ID: 25817822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
    Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
    J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
    Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
    Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of prostate cancer progression by galectin-3.
    Wang Y; Nangia-Makker P; Tait L; Balan V; Hogan V; Pienta KJ; Raz A
    Am J Pathol; 2009 Apr; 174(4):1515-23. PubMed ID: 19286570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer.
    Piao YR; Piao LZ; Zhu LH; Jin ZH; Dong XZ
    Asian Pac J Cancer Prev; 2013; 14(6):3897-901. PubMed ID: 23886204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.
    Kwok WK; Ling MT; Lee TW; Lau TC; Zhou C; Zhang X; Chua CW; Chan KW; Chan FL; Glackin C; Wong YC; Wang X
    Cancer Res; 2005 Jun; 65(12):5153-62. PubMed ID: 15958559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel biomarkers for prostate cancer including noncoding transcripts.
    Romanuik TL; Ueda T; Le N; Haile S; Yong TM; Thomson T; Vessella RL; Sadar MD
    Am J Pathol; 2009 Dec; 175(6):2264-76. PubMed ID: 19893039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
    Borre M; Stausbol-Gron B; Overgaard J
    J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.
    Coppola V; Musumeci M; Patrizii M; Cannistraci A; Addario A; Maugeri-Saccà M; Biffoni M; Francescangeli F; Cordenonsi M; Piccolo S; Memeo L; Pagliuca A; Muto G; Zeuner A; De Maria R; Bonci D
    Oncogene; 2013 Apr; 32(14):1843-53. PubMed ID: 22614007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
    Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
    Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
    Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
    Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential role of Sloan-Kettering Institute (Ski) protein in Nodal and transforming growth factor-beta (TGF-β)-induced Smad signaling in prostate cancer cells.
    Vo BT; Cody B; Cao Y; Khan SA
    Carcinogenesis; 2012 Nov; 33(11):2054-64. PubMed ID: 22843506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer.
    Hennigs JK; Minner S; Tennstedt P; Löser R; Huland H; Klose H; Graefen M; Schlomm T; Sauter G; Bokemeyer C; Honecker F
    Sci Rep; 2020 Feb; 10(1):3250. PubMed ID: 32094363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.